Shares in TearLab Corp. (NSDQ:TEAR) said last week that its board approved a 1-for-1o reverse split of its common stock. The company’s shares have fallen nearly 20% since the beginning of the month. The San Diego, Calif.-based company’s move reduced the total number of authorized shares of its common stock from 95 million t0 9.5 […]
Elixir Medical’s DeSyne stent tops Medtronic’s Endeavor after 5 years
Elixir Medical‘s novolimus-eluting stent, DeSyne, outperformed Medtronic‘s (NYSE:MDT) zotarolimus-eluting stent, Endeavor, according to long-term data from Elixir’s Excella II trial. The study enrolled 210 patients with 2 or more de novo lesions in 2 different epicardial vessels. Researchers randomly assigned patients in a 2:1 ratio to the novolimus-eluting stent or the zotarolimus-eluting stent. The device emits a low […]
Researchers develop 3D-printed, bioabsorbable scaffold for ACL reconstruction
Researchers at the Mayo Clinic‘s tissue engineering and biomaterials laboratory have developed a 3D-printed, porous scaffold for the delayed delivery of recombinant-human bone morphogenetic protein 2, rhBMP-2, to facilitate bone regeneration in patients undergoing ACL reconstruction. The team’s work developing the scaffold and comparing different delivery methods for rhBMP-2 was published this week in Tissue Engineering. […]
Clearside bails on AMD, all-in on diabetic macular edema
Clearside Biomedical (NSDQ:CLSD) said today it will redirect its R&D efforts from its pre-clinical axitinib wet age-related macular degeneration therapy to its Zuprata diabetic macular edema treatment. The Alpharetta, Ga.-based company said that recent trial results from other companies investigating combination therapies for wet AMD have led Clearside to reconsider its proprietary suspension formulation of […]
Report finds pharma companies limited January list price hikes
Drug-makers didn’t raise list prices for as many drugs in January compared to last year and they initiated fewer hikes of 10% or more, according to analysis by Raymond James & Associates. Although 5.5% of price increases reached the 10% level in January this year, 15% did last year and 20% did 2 years ago. […]
Study: Nanotechnology could cut dose of HIV treatment in half
Researchers from the University of Liverpool presented data this week evaluating the use of nanotechnology to improve drug therapies for HIV patients. The team touted its data at the Conference on Retroviruses and Opportunistic Infections in Seattle. The trial enrolled healthy patients and evaluated the use of orally-dosed solid drug nanoparticles to optimize HIV therapy, according […]
OncoSec wins fast track designation for electroporation combo therapy
OncoSec Medical (NSDQ:ONCS) said today that it won Fast Track Designation from the FDA for its ImmunoPulse IL-12 electroporation gene therapy for the treatment of metastatic melanoma. The biotech company’s electroporation device is designed to locally deliver DNA-based interleukin-12 to stimulate the immune system and fight off cancer cells. The ImmunoPulse device delivers a sequence […]
FDA accepts AcelRx’s NDA for Dsuvia pain reliever
AcelRx Pharmaceuticals (NSDQ:ACRX) said today that the FDA accepted the company’s New Drug Application for its Dsuvia pain relief therapy. The federal watchdog set a target decision date for October 12 this year. The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator to patients with moderate-to-severe […]
Intersect ENT wins FDA nod for Propel Contour steroid-releasing implant
Intersect ENT (NSDQ:XENT) said today that it won FDA approval for its Propel Contour steroid-releasing implant for the treatment of chronic sinusitis in the frontal and maxillary sinsuses. The Menlo Park, Calif.-based company’s portfolio of steroid-releasing implants are used in patients undergoing ethmoid, frontal or maxillary surgeries to treat chronic sinusitis. “The approval of Propel […]
Bristol-Myers prices $1.5B senior notes offering
Bristol-Myers Squibb (NYSE:BMY) said today that it has agreed to sell $1.5 billion of senior unsecured notes in an underwritten public offering. The offering includes $750 million in 1.6% senior notes due in 2019 and $750 million in 3.3% senior notes due in 2027, according to the New York-based company. Bristol-Myers said it plans to […]